Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1988 Mar;47(3):241–246. doi: 10.1136/ard.47.3.241

Inhibition of leucotriene B4 synthesis by BW 755c does not reduce polymorphonuclear leucocyte (PMNL) accumulation induced by monosodium urate crystals.

M J Forrest 1, V Zammit 1, P M Brooks 1
PMCID: PMC1003492  PMID: 2833186

Abstract

Monosodium urate (MSU) crystals induce an inflammatory response when injected into the rat subcutaneous air pouch, which is characterised by polymorphonuclear leucocyte (PMNL) accumulation and plasma leakage. The arachidonic acid metabolites leucotriene B4 (LTB4), prostaglandin E2 (PGE2), 6-oxo-prostaglandin F1 alpha, (6-oxo-PGF1 alpha), and thromboxane B2 (TXB2) are found in increased concentrations in MSU induced exudates compared with animals injected with phosphate buffered saline (PBS). Pretreatment of animals with BW 755c significantly reduced the concentration of both lipoxygenase and cyclo-oxygenase derived arachidonic acid metabolites. Although BW 755c reduced MSU crystal induced plasma leakage, it did not affect PMNL accumulation. Pretreatment of animals with indomethacin selectively inhibited the generation of cyclo-oxygenase derived arachidonic acid metabolites and reduced MSU crystal induced plasma leakage but had no effect on PMNL accumulation. The inhibition of plasma leakage by either BW 755c or indomethacin was reversed by prostaglandin E2 (1 microgram/ml), which itself produced a significant increase in plasma leakage. The injection of purified LTB4 (4 ng/ml or 40 ng/ml) did not induce either plasma leakage or PMNL accumulation within the air pouch. These data suggest that although MSU crystals stimulate LTB4 production, LTB4 is not the mediator of MSU crystal induced PMNL accumulation. Cyclo-oxygenase products of arachidonic acid metabolism (e.g., PGE2), however, appear to play a part in MSU crystal induced plasma leakage.

Full text

PDF
241

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bhattacherjee P., Hammond B., Salmon J. A., Stepney R., Eakins K. E. Chemotactic response to some arachidonic acid lipoxygenase products in the rabbit eye. Eur J Pharmacol. 1981 Jul 17;73(1):21–28. doi: 10.1016/0014-2999(81)90141-2. [DOI] [PubMed] [Google Scholar]
  2. Bray M. A., Cunningham F. M., Ford-Hutchinson A. W., Smith M. J. Leukotriene B4: a mediator of vascular permeability. Br J Pharmacol. 1981 Mar;72(3):483–486. doi: 10.1111/j.1476-5381.1981.tb11000.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bray M. A., Ford-Hutchinson A. W., Smith M. J. Leukotriene B4: an inflammatory mediator in vivo. Prostaglandins. 1981 Aug;22(2):213–222. doi: 10.1016/0090-6980(81)90036-8. [DOI] [PubMed] [Google Scholar]
  4. Bray M. A. The pharmacology and pathophysiology of leukotriene B4. Br Med Bull. 1983 Jul;39(3):249–254. doi: 10.1093/oxfordjournals.bmb.a071828. [DOI] [PubMed] [Google Scholar]
  5. Brooks P. M., Burton D., Forrest M. J. Crystal-induced inflammation in the rat subcutaneous air-pouch. Br J Pharmacol. 1987 Feb;90(2):413–419. doi: 10.1111/j.1476-5381.1987.tb08971.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Camp R., Jones R. R., Brain S., Woollard P., Greaves M. Production of intraepidermal microabscesses by topical application of leukotriene B4. J Invest Dermatol. 1984 Feb;82(2):202–204. doi: 10.1111/1523-1747.ep12259945. [DOI] [PubMed] [Google Scholar]
  7. Carlson R. P., Chang J., Datko L. J., Lewis A. J. Questionable role of leukotriene B4 in monosodium urate (MSU)-induced synovitis in the dog. Prostaglandins. 1986 Oct;32(4):579–585. doi: 10.1016/0090-6980(86)90039-0. [DOI] [PubMed] [Google Scholar]
  8. Denko C. W., Whitehouse M. W. Experimental inflammation induced by naturally occurring microcrystalline calcium salts. J Rheumatol. 1976 Mar;3(1):54–62. [PubMed] [Google Scholar]
  9. Di Giovine F. S., Malawista S. E., Nuki G., Duff G. W. Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. J Immunol. 1987 May 15;138(10):3213–3218. [PubMed] [Google Scholar]
  10. Foster S. J., McCormick M. E., Howarth A., Aked D. Leukocyte recruitment in the subcutaneous sponge implant model of acute inflammation in the rat is not mediated by leukotriene B1. Biochem Pharmacol. 1986 May 15;35(10):1709–1717. doi: 10.1016/0006-2952(86)90328-x. [DOI] [PubMed] [Google Scholar]
  11. Goetzl E. J., Pickett W. C. The human PMN leukocyte chemotactic activity of complex hydroxy-eicosatetraenoic acids (HETEs). J Immunol. 1980 Oct;125(4):1789–1791. [PubMed] [Google Scholar]
  12. Hasselbacher P. C3 activation by monosodium urate monohydrate and other crystalline material. Arthritis Rheum. 1979 Jun;22(6):571–578. doi: 10.1002/art.1780220603. [DOI] [PubMed] [Google Scholar]
  13. Higgs G. A., Flower R. J., Vane J. R. A new approach to anti-inflammatory drugs. Biochem Pharmacol. 1979 Jun 15;28(12):1959–1961. doi: 10.1016/0006-2952(79)90651-8. [DOI] [PubMed] [Google Scholar]
  14. Higgs G. A., Salmon J. A., Spayne J. A. The inflammatory effects of hydroperoxy and hydroxy acid products of arachidonate lipoxygenase in rabbit skin. Br J Pharmacol. 1981 Oct;74(2):429–433. doi: 10.1111/j.1476-5381.1981.tb09988.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kowanko I. C., Gordon T. P., Rozenbilds M. A., Brooks P. M., Roberts-Thomson P. J. The subcutaneous air pouch model of synovium and the inflammatory response to heat aggregated gammaglobulin. Agents Actions. 1986 Jun;18(3-4):421–428. doi: 10.1007/BF01965007. [DOI] [PubMed] [Google Scholar]
  16. Kreisle R. A., Parker C. W., Griffin G. L., Senior R. M., Stenson W. F. Studies of leukotriene B4-specific binding and function in rat polymorphonuclear leukocytes: absence of a chemotactic response. J Immunol. 1985 May;134(5):3356–3363. [PubMed] [Google Scholar]
  17. Palmer R. M., Stepney R. J., Higgs G. A., Eakins K. E. Chemokinetic activity of arachidonic and lipoxygenase products on leuocyctes of different species. Prostaglandins. 1980 Aug;20(2):411–418. doi: 10.1016/s0090-6980(80)80058-x. [DOI] [PubMed] [Google Scholar]
  18. Rae S. A., Davidson E. M., Smith M. J. Leukotriene B4, an inflammatory mediator in gout. Lancet. 1982 Nov 20;2(8308):1122–1124. doi: 10.1016/s0140-6736(82)92785-4. [DOI] [PubMed] [Google Scholar]
  19. Serhan C. N., Lundberg U., Weissmann G., Samuelsson B. Formation of leukotrienes and hydroxy acids by human neutrophils and platelets exposed to monosodium urate. Prostaglandins. 1984 Apr;27(4):563–581. doi: 10.1016/0090-6980(84)90092-3. [DOI] [PubMed] [Google Scholar]
  20. Smith M. J., Ford-Hutchinson A. W., Bray M. A. Leukotriene B: a potential mediator of inflammation. J Pharm Pharmacol. 1980 Jul;32(7):517–518. doi: 10.1111/j.2042-7158.1980.tb12985.x. [DOI] [PubMed] [Google Scholar]
  21. Soter N. A., Lewis R. A., Corey E. J., Austen K. F. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol. 1983 Feb;80(2):115–119. doi: 10.1111/1523-1747.ep12531738. [DOI] [PubMed] [Google Scholar]
  22. Takagi T., Forrest M. J., Brooks P. M. A pharmacological and histological examination of the microcirculation of the rat subcutaneous air-pouch: microcirculation of the rat air-pouch. Pathology. 1987 Jul;19(3):294–298. doi: 10.3109/00313028709066567. [DOI] [PubMed] [Google Scholar]
  23. Wedmore C. V., Williams T. J. Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature. 1981 Feb 19;289(5799):646–650. doi: 10.1038/289646a0. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES